Karnataka warns people against 14 ‘substandard' drugs; directs sellers not to stock or sell THESE medicines
The Karnataka government declared 14 drugs manufactured by different companies 'substandard' on Wednesday, 25 June 2025, and warned people against the public consumption of the same, reported the news agency PTI.
The Karnataka Food Safety and Drug Administration department ordered the chemists, wholesalers, doctors, hospitals, and nursing homes not to keep stock of these drugs, and also directed against selling or usage of these medicines and cosmetics, according to the agency report citing the official statement.
'In case they hold any stock, they are requested to inform the concerned area Drugs Inspector or Assistant Drugs Controller. The public is also advised not to use these drugs or cosmetics,' said the FSDA department, according to the agency report.
1. Compound sodium lactate injection IP (Ringer-Lactate solution for injection) — Manufactured by Ultra Laboratories (batch no: KI124110) and Tam Bran Pharmaceuticals.
2. Pomol-650 (Paracetamol tablets I P 650 mg) by Aban Pharmaceuticals (batch no: 13-4536).
3. MITO Q7 Syrup by Bion Therapeutics India (batch no: CHS-40170).
These are among the 14 drugs which were marked as 'substandard' by the Karnataka Food Safety and Drug Administration department on Wednesday, 25 June 2025.
The department also requested strict compliance to be imposed on these companies and drugs to safeguard public health, reported the news agency.
According to Mint's earlier report, India is aiming to give a significant boost to its production-linked incentive (PLI) schemes for drug manufacturing to reduce the nation's pharma sector dependence on China imports.
The updated PLI scheme will include more molecules used in manufacturing key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs), according to the 3 June 2025 report citing official communication.
Details on such incentives as allocation, capacity, and incentive ceiling for the upgraded drug PLI scheme are being worked on, according to the Mint's report, citing a department official.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
4 hours ago
- The Print
Over 20 lakh from tribal areas screened for sickle cell anaemia in past 8 years: CSIR DG
The genetic disorder affects red blood cells, making them sickle-shaped, instead of the usual round one. Common symptoms include acute painful episodes, blocking of blood vessels and possible organ damage. Introduced in the Union Budget 2023 and launched in July the same year, the 'National Sickle Cell Anaemia Elimination Mission' is aimed at eliminating the blood disease from the country by the end of 2047. New Delhi, Jun 27 (PTI) More than 20 lakh people from tribal areas have been screened since we started the sickle cell anaemia project eight years back, said CSIR's Director General Nallathamby Kalaiselvi, terming it among the institute's more successful missions. Speaking to PTI Videos, Kalaiselvi, who is also the Secretary of Department of Scientific and Industrial Research, said, 'While the country started talking about sickle cell anaemia only three years back, Council of Scientific and Industrial Research (CSIR) started addressing sickle cell anaemia eight years back, thanks to the Ministry of Tribal Affairs, who gave the funding for the first five to six years.' 'It is actually one of our very visionary, successful missions, I would say,' she said. Kalaiselvi made history when she was appointed the first woman chief of CSIR — the country's largest research and development organisation, with 37 national laboratories and over 3,400 scientists. She explained that the sickle cell anaemia mission was divided into three parts, first being the screening and surveillance done by the Centre for Cellular and Molecular Biology (CCMB) in Hyderabad. 'If you just see the screening and surveillance, it is a great success story for our team, headed by Dr Giriraj Chandak (at CCMB), which went to Raipur, Bilaspur and other places,' Kalaiselvi said, adding that 20 lakh people have been screened so far. 'They interacted with the tribal communities and provided counselling pre and post-marriage, before and during pregnancy, and also after child birth,' she explained. 'The second part looked at drugs and medicines that could be utilised for sickle cell anaemia. This was headed by the Indian Institute of Chemical Technology,' Kalaiselvi added. The third part, involving genome sequencing and editing, was headed by the Institute of Genomics and Integrative Biology, New Delhi, the 58-year-old said. Kalaiselvi said, 'Now, after five to six years, we realised the great potential of coming up with a sickle cell anaemia detection kit, developed by (Chandak's) group.' Explaining the working of the kit, she said, 'Using one drop of dried blood, you can easily understand if you have a threat of developing sickle cell anaemia… if you are a carrier or patient… or what is the severity of the condition.' 'It is going to cost even less than Rs 100, and you need not depend upon sophisticated instruments from now onwards,' she added. Born in February, 1967, in Tamil Nadu's Tirunelveli district, Kalaiselvi graduated with a Bachelors in Chemistry from Government Arts College in Tirunelveli. She obtained a Post Graduate Degree in Chemistry from Coimbatore's Government Arts College and completed her PhD at Annamalai University, Chidambaram. Kalaiselvi also talked about introducing lithium and sodium ion batteries in the consumer market. 'Thanks to the Government of India, with the 'Production Linked Incentive' (PLI) scheme, we have established a full-fledged facility in Chennai wherein one can produce 1,000 cylindrical lithium ion cells,' the director general said. The PLI scheme is among the Central government's efforts directed at positioning the country as a global manufacturing hub through innovation, efficiency and competitiveness. Kalaiselvi also said that lithium resources have been identified in India, at least in four places, even as she desisted from naming them. PTI DR KRS KRS This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
The Print
7 hours ago
- The Print
Mother seeks access to dead son's semen; HC asks fertility centre to preserve frozen sample
A bench of Justice Manish Pitale on June 25 noted that if the frozen semen of the deceased man is discarded pending hearing of the plea, then it would become infructuous. The court posted the petition for further hearing on July 30. The woman moved the HC after the fertility centre refused to release the frozen semen to her as the man, in his consent forms, had sought for the sperm carrying fluid to be discarded post-death. The man had chosen to freeze his semen when he was undergoing chemotherapy, a cancer treatment. Mumbai, Jun 27 (PTI) The Bombay High Court, in an interim order, has directed a city-based fertility centre to preserve the frozen semen of a deceased unmarried man pending hearing of a petition by his mother who wants to use the fluid to continue the family line. 'In the meanwhile, as an interim direction, the fertility centre is directed to ensure safe-keeping and storage of the frozen sample of the deceased, during pendency of the petition,' the court ordered. The bench noted that the petition raises important questions with regard to the manner in which the semen of a person is to be preserved after his death under provisions of the Assisted Reproductive Technology (Regulation) Act, 2021. The court pointed out that in the present case, the man was unmarried at the time of his death in February. The woman, in her plea, argued her son had, without consulting family members, in his consent forms agreed to have the frozen semen discarded if he dies. After his death, the mother sought the Mumbai-based fertility centre to provide access to transfer the sample to a Gujarat-based IVF centre for future course of action. The fertility centre, however, refused and asked the mother to obtain authorization from court under the new Act, which seeks to regulate and supervise assisted reproductive technology (ART) clinics. The legislation also aims to ensure ethical practices, prevent misuse, and protect the rights of individuals seeking ART services. PTI SP RSY This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Hindustan Times
7 hours ago
- Hindustan Times
Dead man's mom in Mumbai wants his frozen semen to 'continue family line'
A unique legal battle is brewing in Mumbai, involving a mother's unexpected quest to become a grandmother, using her dead son's frozen sperm. The man's consent form, he clearly stated that the sperm should be discarded if he died. (Representational Image) The man, who was unmarried and undergoing chemotherapy, had decided to freeze his semen before starting cancer treatment. But in his consent form, he clearly stated that the sperm should be discarded if he died. Fast forward to earlier this year: the man passed away, and his grieving mother, hoping to continue the family lineage, approached the fertility centre where the sample was stored, news agency PTI reported. She requested they release the frozen semen so she could transfer it to an IVF centre in Gujarat for possible use in assisted reproduction. But there was a catch, the clinic refused. They cited the man's own instructions to discard the sample posthumously and pointed to the Assisted Reproductive Technology (Regulation) Act, 2021, which mandates court approval in such cases to avoid ethical and legal complications, the report added. (Also Read: Indian-origin woman rants about zero veg food at US work event: 'I walked out so disappointed') Mother moves court Determined, the mother took the matter to the Bombay High Court, arguing that her son had signed the consent form without discussing it with his family. She believes the sperm shouldn't be discarded and deserves a second chance, possibly one that includes grandkids. In response, the court stepped in with an interim order on June 25, directing the fertility centre to preserve the frozen semen until the matter is heard in full on July 30. The judge also noted that the case raises important questions under the ART law, particularly around what happens to preserved genetic material after someone dies. (With PTI inputs) (Also Read: Indian-origin CEO posts about near-heart attack, internet slams him for turning hospital photo into LinkedIn content)
